Harun Kundi1,2, Jeffrey J Popma1,2, Matthew R Reynolds2,3, Jordan B Strom1, Duane S Pinto1, Linda R Valsdottir1, Changyu Shen1, Eunhee Choi1, Robert W Yeh1,2. 1. Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, 375 Longwood Ave, Fourth Floor, Boston, MA, USA. 2. Baim Institute for Clinical Research, 930 Commonwealth Avenue #3, Boston, MA, USA. 3. Division of Cardiology, Lahey Hospital & Medical Center, 41 Burlington Mall Road, Burlington, MA, USA.
Abstract
AIMS: We sought to identify the prevalence and related outcomes of frail individuals undergoing transcatheter mitral valve repair and transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS: Patients aged 65 and older were included in the study if they had at least one procedural code for transcatheter mitral valve repair or TAVR between 1 January 2016 and 31 December 2016 in the Centers for Medicare and Medicaid Services Medicare Provider and Review database. The Hospital Frailty Risk Score, an International Classification of Diseases, Tenth Revision (ICD-10) claims-based score, was used to identify frailty and the primary outcome was all-cause 1-year mortality. A total of 3746 (11.6%) patients underwent transcatheter mitral valve repair and 28 531 (88.4%) underwent TAVR. In the transcatheter mitral valve repair and TAVR populations, respectively, there were 1903 (50.8%) and 14 938 (52.4%) patients defined as low risk for frailty (score <5), 1476 (39.4%) and 11 268 (39.5%) defined as intermediate risk (score 5-15), and 367 (9.8%) and 2325 (8.1%) defined as high risk (score >15). One-year mortality was 12.8% in low-risk patients, 29.7% in intermediate-risk patients, and 40.9% in high-risk patients undergoing transcatheter mitral valve repair (log rank P < 0.001). In patients undergoing TAVR, 1-year mortality rates were 7.6% in low-risk patients, 17.6% in intermediate-risk patients, and 30.1% in high-risk patients (log rank P < 0.001). CONCLUSIONS: This study successfully identified individuals at greater risk of short- and long-term mortality after undergoing transcatheter valve therapies in an elderly population in the USA using the ICD-10 claims-based Hospital Frailty Risk Score. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: We sought to identify the prevalence and related outcomes of frail individuals undergoing transcatheter mitral valve repair and transcatheter aortic valve replacement (TAVR). METHODS AND RESULTS:Patients aged 65 and older were included in the study if they had at least one procedural code for transcatheter mitral valve repair or TAVR between 1 January 2016 and 31 December 2016 in the Centers for Medicare and Medicaid Services Medicare Provider and Review database. The Hospital Frailty Risk Score, an International Classification of Diseases, Tenth Revision (ICD-10) claims-based score, was used to identify frailty and the primary outcome was all-cause 1-year mortality. A total of 3746 (11.6%) patients underwent transcatheter mitral valve repair and 28 531 (88.4%) underwent TAVR. In the transcatheter mitral valve repair and TAVR populations, respectively, there were 1903 (50.8%) and 14 938 (52.4%) patients defined as low risk for frailty (score <5), 1476 (39.4%) and 11 268 (39.5%) defined as intermediate risk (score 5-15), and 367 (9.8%) and 2325 (8.1%) defined as high risk (score >15). One-year mortality was 12.8% in low-risk patients, 29.7% in intermediate-risk patients, and 40.9% in high-risk patients undergoing transcatheter mitral valve repair (log rank P < 0.001). In patients undergoing TAVR, 1-year mortality rates were 7.6% in low-risk patients, 17.6% in intermediate-risk patients, and 30.1% in high-risk patients (log rank P < 0.001). CONCLUSIONS: This study successfully identified individuals at greater risk of short- and long-term mortality after undergoing transcatheter valve therapies in an elderly population in the USA using the ICD-10 claims-based Hospital Frailty Risk Score. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Keturah R Faurot; Michele Jonsson Funk; Virginia Pate; M Alan Brookhart; Amanda Patrick; Laura C Hanson; Wendy Camelo Castillo; Til Stürmer Journal: Pharmacoepidemiol Drug Saf Date: 2014-10-21 Impact factor: 2.890
Authors: Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano Journal: Eur Heart J Date: 2017-09-21 Impact factor: 29.983
Authors: Dae Hyun Kim; Sebastian Schneeweiss; Robert J Glynn; Lewis A Lipsitz; Kenneth Rockwood; Jerry Avorn Journal: J Gerontol A Biol Sci Med Sci Date: 2018-06-14 Impact factor: 6.053
Authors: Andreas W Schoenenberger; André Moser; Dominic Bertschi; Peter Wenaweser; Stephan Windecker; Thierry Carrel; Andreas E Stuck; Stefan Stortecky Journal: JACC Cardiovasc Interv Date: 2018-02-26 Impact factor: 11.195
Authors: Jonathan Afilalo; Sandra Lauck; Dae H Kim; Thierry Lefèvre; Nicolo Piazza; Kevin Lachapelle; Giuseppe Martucci; Andre Lamy; Marino Labinaz; Mark D Peterson; Rakesh C Arora; Nicolas Noiseux; Andrew Rassi; Igor F Palacios; Philippe Généreux; Brian R Lindman; Anita W Asgar; Caroline A Kim; Amanda Trnkus; José A Morais; Yves Langlois; Lawrence G Rudski; Jean-Francois Morin; Jeffrey J Popma; John G Webb; Louis P Perrault Journal: J Am Coll Cardiol Date: 2017-07-07 Impact factor: 24.094
Authors: Suzanne V Arnold; Jonathan Afilalo; John A Spertus; Yuanyuan Tang; Suzanne J Baron; Philip G Jones; Michael J Reardon; Steven J Yakubov; David H Adams; David J Cohen Journal: J Am Coll Cardiol Date: 2016-10-25 Impact factor: 24.094
Authors: Marc L Schermerhorn; Dominique B Buck; A James O'Malley; Thomas Curran; John C McCallum; Jeremy Darling; Bruce E Landon Journal: N Engl J Med Date: 2015-07-23 Impact factor: 91.245
Authors: Jodi B Segal; Hsien-Yen Chang; Yu Du; Jeremy D Walston; Michelle C Carlson; Ravi Varadhan Journal: Med Care Date: 2017-07 Impact factor: 2.983
Authors: Jordan B Strom; Kamil F Faridi; Neel M Butala; Yuansong Zhao; Hector Tamez; Linda R Valsdottir; J Matthew Brennan; Changyu Shen; Jeffrey J Popma; Dhruv S Kazi; Robert W Yeh Journal: Circulation Date: 2020-05-21 Impact factor: 29.690
Authors: Shivani Shah; David S Goldberg; David E Kaplan; Vinay Sundaram; Tamar H Taddei; Nadim Mahmud Journal: Liver Transpl Date: 2020-10-28 Impact factor: 5.799
Authors: Britt Borregaard; Jordi S Dahl; Sandra B Lauck; Jesper Ryg; Selina K Berg; Ola Ekholm; Jeroen M Hendriks; Lars P S Riber; Tone M Norekvål; Jacob E Møller Journal: Int J Cardiol Heart Vasc Date: 2020-11-13
Authors: Marlena Schnieder; Mathias Bähr; Mareike Kirsch; Ilko Maier; Daniel Behme; Christian Heiner Riedel; Marios-Nikos Psychogios; Alex Brehm; Jan Liman; Christine A F von Arnim Journal: J Clin Med Date: 2021-05-18 Impact factor: 4.241
Authors: Amgad Mentias; Marwan Saad; Milind Y Desai; Phillip A Horwitz; James D Rossen; Sidakpal Panaich; Ayman Elbadawi; Abdul Qazi; Paul Sorajja; Hani Jneid; Samir Kapadia; Barry London; Mary S Vaughan Sarrazin Journal: J Am Heart Assoc Date: 2019-10-31 Impact factor: 5.501
Authors: Min Ji Kwak; Rafia Rasu; Robert O Morgan; Jessica Lee; Nahid J Rianon; Holly M Holmes; Abhijeet Dhoble; Dae Hyun Kim Journal: J Health Econ Outcomes Res Date: 2020-10-05